BioLine RX Ltd
BLRX4.485USD
+0.045+1.01%
終値 06/25, 16:00（ET）15分遅れの株価
10.01B時価総額
損失額直近12ヶ月PER
詳細情報 BioLine RX Ltd 企業名
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
企業情報
企業コードBLRX
会社名BioLine RX Ltd
上場日Jan 30, 2007
設立日2003
最高経営責任者「CEO」Mr. Philip Adam (Phil) Serlin
従業員数28
証券種類Ordinary Share
決算期末Jan 30
本社所在地Modi'in Technology Park
都市MODIIN
証券取引所Tel Aviv Stock Exchange
国Israel
郵便番号7177871
電話番号97286429100
ウェブサイトhttps://www.biolinerx.com/
企業コードBLRX
上場日Jan 30, 2007
設立日2003
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Hillit Mannor Shachar
Dr. Hillit Mannor Shachar
Vice President - Business Development
Vice President - Business Development
--
--
Dr. Sandra Panem, Ph.D.
Dr. Sandra Panem, Ph.D.
Director
Director
--
--
Mr. Philip Adam (Phil) Serlin
Mr. Philip Adam (Phil) Serlin
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Michael J. Anghel
Dr. Michael J. Anghel
Director
Director
--
--
Dr. Ella Sorani
Dr. Ella Sorani
Vice President - Development
Vice President - Development
--
--
Dr. Barbara-Jean (BJ) Bormann
Dr. Barbara-Jean (BJ) Bormann
Director
Director
--
--
Mr. Gal Cohen
Mr. Gal Cohen
Independent Director
Independent Director
--
--
Ms. Nurit Benjamini
Ms. Nurit Benjamini
External Director
External Director
--
--
Ms. Mali Zeevi
Ms. Mali Zeevi
Chief Financial Officer
Chief Financial Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Hillit Mannor Shachar
Dr. Hillit Mannor Shachar
Vice President - Business Development
Vice President - Business Development
--
--
Dr. Sandra Panem, Ph.D.
Dr. Sandra Panem, Ph.D.
Director
Director
--
--
Mr. Philip Adam (Phil) Serlin
Mr. Philip Adam (Phil) Serlin
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Michael J. Anghel
Dr. Michael J. Anghel
Director
Director
--
--
Dr. Ella Sorani
Dr. Ella Sorani
Vice President - Development
Vice President - Development
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Sat, May 17
更新時刻: Sat, May 17
株主統計
種類
株主統計
株主統計
比率
Hong Seng Technology Ltd
4.01%
Intracoastal Capital, L.L.C.
0.07%
Wells Fargo Advisors
0.07%
BNP Paribas Securities Corp. North America
0.04%
Rhumbline Advisers Ltd. Partnership
0.04%
Other
95.77%
株主統計
株主統計
比率
Hong Seng Technology Ltd
4.01%
Intracoastal Capital, L.L.C.
0.07%
Wells Fargo Advisors
0.07%
BNP Paribas Securities Corp. North America
0.04%
Rhumbline Advisers Ltd. Partnership
0.04%
Other
95.77%
種類
株主統計
比率
Corporation
4.08%
Research Firm
0.14%
Investment Advisor
0.07%
Other
95.71%
機関投資家保有株
更新時刻: Sat, Feb 22
更新時刻: Sat, Feb 22
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q1
63
215.61K
5.79%
-104.86K
2024Q4
63
222.04K
6.08%
+67.69K
2024Q3
62
233.17K
7.79%
-25.85K
2024Q2
66
277.79K
10.04%
+89.80K
2024Q1
64
205.72K
6.62%
+27.03K
2023Q4
67
200.88K
6.35%
-8.70K
2023Q3
69
34.99K
2.17%
-169.90K
2023Q2
63
31.93K
2.08%
-207.57K
2023Q1
65
80.66K
5.25%
-259.21K
2022Q4
64
168.22K
10.94%
-244.43K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Hong Seng Technology Ltd
170.73K
4.59%
+170.73K
--
Oct 09, 2023
BNP Paribas Securities Corp. North America
1.43K
0.04%
+1.43K
--
Dec 31, 2024
Rhumbline Advisers Ltd. Partnership
1.07K
0.03%
+259.00
+31.78%
Dec 31, 2024
Morgan Stanley & Co. LLC
1.98K
0.05%
-2.78K
-58.44%
Dec 31, 2024
詳細を見る
関連ETF
更新時刻: Fri, Jun 6
更新時刻: Fri, Jun 6
銘柄名
比率
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Jan 17, 2025
Merger
40<1
Jan 17, 2025
Merger
40<1
Jan 17, 2025
Merger
40<1
Jan 17, 2025
Merger
40<1
日付
種類
比率
Jan 17, 2025
Merger
40<1
Jan 17, 2025
Merger
40<1
Jan 17, 2025
Merger
40<1
Jan 17, 2025
Merger
40<1
